ReviewAnnals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology2017
Single recombinant and purified major allergens and peptides: How they are made and how they change allergy diagnosis and treatment.
Review in Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- A Simple Method to Produce Recombinant Mammalian Serum Albumins inInternational journal of molecular sciences · 2026Article
- Major Cat Allergen Fel d 4: Structure and Identification of a Cross-Reactive IgE-Epitope-Containing Area.Allergy · 2026Article
- Article
- Art an 3 as a candidate recombinant antigen for Artemisia pollen immunotherapy: comparative efficacy and mechanistic insights.Frontiers in medicine · 2026Article
- A novel recognition of the major allergen, Hum j 1, fromThe World Allergy Organization journal · 2025Article
- Enhancing production and assessing IgE reactivity of dog allergen Can f 6 in Pichia pastoris and Escherichia coli.Applied microbiology and biotechnology · 2025Article
- Structural analysis of human IgE monoclonal antibody epitopes on dust mite allergen Der p 2.The Journal of allergy and clinical immunology · 2024Article
- Non-Specific Lipid Transfer Protein Amb a 6 Is a Source-Specific Important Allergenic Molecule in Ragweed Pollen.International journal of molecular sciences · 2024Article
- Pru p 3-specific IgE affinity is crucial in severe peach-allergy patients.The World Allergy Organization journal · 2024Article
- Insect Cell-Expressed Major Ragweed Allergen Amb a 1.01 Exhibits Similar Allergenic Properties to Its Natural Counterpart from Common Ragweed Pollen.International journal of molecular sciences · 2024Article
- Comparison of Skin Prick Tests (SPT), Intradermal Tests (IDT) andAnimals : an open access journal from MDPI · 2023Article
- Selected Technical Aspects of Molecular Allergy Diagnostics.Current issues in molecular biology · 2023Review
- A genome-wide association study for allergen component sensitizations identifies allergen component-specific and allergen protein group-specific associations.The journal of allergy and clinical immunology. Global · 2023Article
- Component-Resolved Diagnosis Based on a Recombinant Variant of Mus m 1 Lipocalin Allergen.International journal of molecular sciences · 2023Article
- Sensitisation to recombinantThe European respiratory journal · 2023Article
- Article
- Article
- The Major Peanut Allergen Ara h 2 Produced inFrontiers in plant science · 2021Article
- Linking cross-reactivity clusters of food and respiratory allergens in PAMD@ to asthma and duration of allergy.The World Allergy Organization journal · 2020Article
- Identification the Cross-Reactive or Species-Specific Allergens ofDiagnostics (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveTo review the current knowledge regarding recombinant and purified allergens and allergen-derived peptides. DATA SOURCES: PubMed, homepages relevant to the topic, and the National Institutes of Health clinical trial database were searched. STUDY SELECTIONS: The literature was screened for studies describing purified and recombinant allergens and allergen-derived peptides. Studies relevant to the topic were included in this review.
resultsAdvantages and drawbacks of pure and defined recombinant allergens and peptides over allergen extracts in the context of allergy research, diagnosis, and allergen immunotherapy are discussed. We describe how these molecules are manufactured, which products are currently available on the market, and what the regulative issues are. We furthermore provide an overview of clinical studies with vaccines based on recombinant allergens and synthetic peptides. The possibility of prophylactic vaccination based on recombinant fusion proteins consisting of viral carrier proteins and allergen-derived peptides without allergenic activity are also discussed.
conclusionDuring the last 25 years more than several hundred allergen sequences were determined, which led to a production of recombinant allergens that mimic biochemically and immunologically their natural counterparts. Especially in Europe, recombinant allergens are increasingly replacing allergen extracts in diagnosis of allergy. Despite many challenges, such as high cost of clinical trials and regulative issues, allergy vaccines based on recombinant allergens and peptides are being developed and will likely soon be available on the market.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.